H.C. Wainwright Reiterates Neutral Rating on BioMarin Pharmaceutical Inc. (BMRN) May 22, 2026 06:51AM
BioMarin Pharmaceutical Inc. (BMRN) PT Lowered to $50 at H.C. Wainwright May 19, 2026 06:48AM
BioMarin Pharmaceutical Inc. (BMRN) PT Raised to $110 at Freedom Broker May 11, 2026 11:31AM
Goldman Sachs Starts BioMarin Pharmaceutical Inc. (BMRN) at Neutral May 11, 2026 05:18AM
BioMarin Pharmaceutical Inc. (BMRN) PT Raised to $116 at Canaccord May 7, 2026 07:58AM
View Older Stories

May 5, 2026 06:00AM BioMarin Pharmaceutical Inc. (BMRN) PT Lowered to $82 at Bernstein SocGen Group
May 5, 2026 04:15AM BioMarin Pharmaceutical Inc. (BMRN) PT Raised to $120 at Evercore ISI
May 4, 2026 04:10PM BioMarin Pharma (BMRN) Tops Q1 EPS by 2c, Beats on Revenue; Offers FY26 EPS Guidance
May 4, 2026 05:54AM BioMarin shares VOXZOGO data showing bone health benefits in children
Apr 27, 2026 06:19AM Morgan Stanley Resumes BioMarin Pharmaceutical Inc. (BMRN) at Overweight
Apr 21, 2026 04:24PM BioMarin appoints Ian Clark as board chair, Richard Meier to retire
Mar 16, 2026 10:07AM Wolfe Research Reiterates Outperform Rating on BioMarin Pharmaceutical Inc. (BMRN): 'we'd be buyer on weakness'
Mar 12, 2026 09:26AM Jefferies Reiterates Buy Rating on BioMarin Pharmaceutical Inc. (BMRN): "data looks viable and is a positive sign"
Mar 12, 2026 09:05AM BioMarin reports early VOXZOGO treatment benefits for achondroplasia
Mar 11, 2026 05:18AM BioMarin Pharmaceutical Inc. (BMRN) PT Lowered to $85 at BofA Securities
Mar 9, 2026 02:38PM Leerink on BioMarin Pharma (BMRN): 'We continue to hold a more cautious view on the outlook for Voxzogo'
Mar 3, 2026 06:12AM BioMarin Pharmaceutical Inc. (BMRN) PT Raised to $105 at Barclays
Mar 2, 2026 04:34PM Truist Securities Reiterates Buy Rating on BioMarin Pharmaceutical Inc. (BMRN)
Mar 2, 2026 09:53AM BioMarin Pharmaceutical Inc. (BMRN) PT Raised to $105 at Freedom Capital Markets
Mar 2, 2026 07:02AM BioMarin Pharmaceutical (BMRN) Reiterated at Overweight by Cantor Fitzgerald After Webinar
Feb 26, 2026 08:23AM BioMarin Pharmaceutical Inc. (BMRN) PT Raised to $104 at Canaccord
Feb 25, 2026 08:20AM BioMarin Pharmaceutical Inc. (BMRN) PT Raised to $94 at Bernstein
Feb 25, 2026 06:38AM BioMarin Pharmaceutical Inc. (BMRN) PT Lowered to $55 at H.C. Wainwright
Feb 24, 2026 06:48AM BioMarin Pharmaceutical Inc. (BMRN) PT Raised to $68 at Stifel
Feb 23, 2026 04:08PM BioMarin Pharma (BMRN) Misses Q4 EPS by 31c; offers guidance
Feb 12, 2026 09:48AM Baird on BioMarin Pharmaceutical Inc. (BMRN): 'Incrementally negative on competitor data'
Feb 12, 2026 07:41AM BioMarin (BMRN), Ascendis (ASND) Trade Lower Following Competitor Data
Jan 20, 2026 01:08AM Canaccord Genuity Upgrades BioMarin Pharmaceutical Inc. (BMRN) to Buy
Jan 12, 2026 04:46PM BioMarin expects $3.2 billion in 2025 revenue, ROCTAVIAN write-down
Jan 12, 2026 04:06PM BioMarin names Arpit Davé as chief digital and information officer
Dec 22, 2025 09:32AM BioMarin Pharmaceutical Inc. (BMRN) PT Raised to $100 at Truist Securities
Dec 22, 2025 09:08AM BioMarin Pharma (BMRN) discontinues development of BMN 349
Dec 22, 2025 07:09AM BioMarin Pharmaceutical Inc. (BMRN) PT Raised to $60 at H.C. Wainwright
Dec 3, 2025 06:40AM Leerink Partners Downgrades BioMarin Pharmaceutical Inc. (BMRN) to Market Perform
Nov 6, 2025 05:09AM Stifel Downgrades BioMarin Pharmaceutical Inc. (BMRN) to Hold, 'Stock Might Even Be Too Cheap, But It's Getting Harder to See the Path'
Nov 3, 2025 07:08AM BioMarin Pharmaceutical Inc. (BMRN) PT Lowered at Bernstein Amid 'Tough NT Setup'
Oct 28, 2025 09:23AM BioMarin Pharmaceutical Inc. (BMRN) PT Lowered at Truist; 'Competitive Pressures Mounting'
Oct 28, 2025 08:43AM BioMarin Pharmaceutical Inc. (BMRN) PT Lowered to $66 at RBC Capital
Oct 28, 2025 06:41AM BioMarin Pharmaceutical Inc. (BMRN) PT Lowered to $55 at H.C. Wainwright
Oct 28, 2025 06:07AM BioMarin Pharmaceutical Inc. (BMRN) PT Lowered to $73 at Stifel
Oct 28, 2025 04:58AM Wolfe on BioMarin Pharmaceutical Inc. (BMRN): 'Divesting Roctavian Is A Rock Solid Move'
Oct 27, 2025 04:08PM BioMarin Pharma (BMRN) Tops Q3 EPS by 20c
Oct 27, 2025 07:41AM Bernstein's US Biotech 3Q25 Preview: 'Expect Beats from ALNY and REGN'
Oct 14, 2025 06:50AM Cantor Fitzgerald Cuts BioMarin (BMRN) PT to $80 Ahead of 3Q Earnings
Sep 8, 2025 06:48AM H.C. Wainwright Starts BioMarin Pharmaceutical Inc. (BMRN) at Neutral
Aug 30, 2025 04:00PM Why public perception matters so much for biotech valuations
Aug 26, 2025 06:35AM Oppenheimer Reiterates Outperform Rating on BioMarin Pharmaceutical Inc. (BMRN)
Aug 19, 2025 07:08AM BioMarin Pharmaceutical Inc. (BMRN) PT Raised to $95 at Bernstein SocGen Group
Aug 5, 2025 09:29AM Stifel Reiterates Buy Rating on BioMarin Pharmaceutical Inc. (BMRN)
Aug 5, 2025 09:07AM Cantor Fitzgerald Reiterates Overweight Rating on BioMarin Pharmaceutical Inc. (BMRN)
Aug 5, 2025 06:46AM Bernstein Reiterates Outperform Rating on BioMarin Pharmaceutical Inc. (BMRN)
Aug 5, 2025 06:20AM TD Cowen Reiterates Buy Rating on BioMarin Pharmaceutical Inc. (BMRN)
Aug 5, 2025 06:12AM BioMarin Pharmaceutical Inc. (BMRN) PT Raised to $114 at UBS
Aug 4, 2025 04:36PM After-hours movers: Palantir, Hims & Hers, Vertex Pharma and more
Aug 4, 2025 04:04PM BioMarin Pharma (BMRN) Tops Q2 EPS by 61c ; Offers Guidance
View Older Stories